Chaudhury I , Sareen A , Raghunandan M , Sobeck A .

	Figure 1. FANCD2 recruits BLMcx to replicating chromatin independently of FANCI. (A) FANCD2, FANCI and BLMcx members exhibit overlapping chromatin-binding patterns in S-phase. Sperm chromatin was replicated in Xenopus S-phase extracts and re-isolated at the indicated time points. Chromatin fractions (lanes 2–8) were analyzed for bound FANCD2, FANCI and BLMcx members. Lane 1: 1 µl extract (loading control). Inset: replication assay. Replication was monitored by pulsing replicating extract aliquots with [α-32P]dGTP at the indicated time windows. (B) Immunodepletion of FANCD2 or FANCI from S-phase extracts does not co-deplete BLMcx proteins. S-phase extracts were mock-, FANCD2 or FANCI-depleted and analyzed for the presence of FANCD2, FANCI and BLMcx members. (C) Recombinant FANCD2WT restores BLMcx recruitment to replicating chromatin in FANCD2/FANCI double-depleted extracts. S-phase extracts were mock depleted (lanes 1 and 2), FANCD2/FANCI depleted (lanes 3 and 4) or FANCD2/FANCI depleted and reconstituted with myc–FANCD2WT (lanes 5 and 6). Sperm chromatin was allowed to replicate in the different extracts, isolated at the indicated time points and analyzed for bound FANCD2, FANCI and BLMcx members. (D) Recombinant FANCD2WT—but not FANCD2K562R—restores BLMcx recruitment to replicating chromatin in FANCD2-depleted extracts. S-phase extracts were mock depleted (lanes 1 and 2), FANCD2 depleted (lanes 3 and 4) or FANCD2 depleted and reconstituted with either myc–FANCD2WT (lanes 5 and 6) or myc-FANCD2K562R (lanes 7 and 8). Sperm chromatin was replicated in the different extracts, re-isolated at indicated time points and analyzed for bound FANCD2, FANCI and BLMcx members. Inset: FANCD2-depleted extracts fail to promote monoubiquitination of supplemented myc-FANCD2WT (owing to low residual FANCI levels) but support chromatin recruitment of non-ubiquitinated myc-FANCD2WT and myc-FANCD2K562R. Chromatin fractions isolated from mock-depleted (lane 1) or FANCD2-depleted (lane 2) extracts, or from FANCD2-depleted extracts supplemented with myc-FANCD2WT (lane 3) or myc-FANCD2K562R (lane 4) were run on a low-percentage gel to distinguish non-ubiquitinated from monoubiquitinated FANCD2 isoforms.
	Figure 2. Defective BLMcx chromatin recruitment in FANCD2-depleted extracts is not caused by replication delay. (A) FANCD2-depleted S-phase extracts exhibit a delay of replication onset. S-phase extracts were mock depleted (lanes 1–4) or FANCD2 depleted (lanes 5–8). Sperm chromatin was added to extracts and replication was monitored by pulsing replicating extract aliquots with [α-32P]dGTP at the indicated time windows. (B) FANCD2—but not FANCI—is responsible for timely replication onset. S-phase extracts were mock depleted (lanes 7 and 8), FANCD2/FANCI depleted (lanes 1 and 2) or FANCD2/FANCI depleted and supplemented with myc-FANCD2WT (lanes 3 and 4) or Flag-FANCIWT (lanes 5 and 6). Sperm chromatin was replicated in the different extracts, and replication was monitored by pulsing extract aliquots with [α-32P]dGTP at the indicated time windows. (C) Parallel to the replication assay shown in Figure 2A, replicating chromatin was re-isolated at indicated time points from mock-depleted extracts (lanes 1–5) or FANCD2-depleted extracts (lanes 6–9), and chromatin fractions were analyzed for bound FANCD2, FANCI and BLMcx members.
	Figure 3. FANCD2 is required for full BLM complex assembly. (A) Input panels: S-phase extracts were mock depleted (lanes 1 and 2) or FANCD2 depleted (lanes 3 and 4), and either untreated (lanes 1 and 3) or incubated with dsDNA fragments for 10 min (lanes 2 and 4). (B) IP panels: the differently depleted egg extracts described in (A) were subjected to IP with rabbit IgG (lanes 1 and 4) or a Xenopus-specific BLM antibody (lanes 2, 3, 5 and 6). Input and IP samples were analyzed for the presence of FANCD2, FANCI and BLMcx proteins.
	Figure 4. FANCD2 protects BLM protein stability. (A) FANCD2 protects BLM protein stability in replicating S-phase extracts. Egg extracts were mock depleted (lanes 1–4), FANCD2 depleted (lanes 5–8) or FANCD2 depleted and treated with MG132 (lanes 9–12). Chromatin was replicated in extracts, and chromatin-containing extract aliquots were taken at indicated time points and analyzed for FANCD2, FANCI and BLMcx members. (B) BLM stabilization does not restore BLMcx chromatin binding in FANCD2-depleted extracts. From replicating extracts described in (A), chromatin fractions were isolated at indicated time points and analyzed for chromatin-bound FANCD2, FANCI and BLMcx. (C) myc-FANCD2WT restores BLM protein stability in FANCD2-depleted extracts. Egg extracts were mock depleted (lanes 1, 4 and 7), FANCD2 depleted (lanes 2, 5 and 8) or FANCD2 depleted and supplemented with myc-FANCD2WT (lanes 3, 6 and 9). Chromatin was replicated in the extracts and chromatin-containing extract aliquots were taken at indicated time points and analyzed for FANCD2, FANCI and BLMcx members. (D) FANCI is dispensable for BLM protein stability. Egg extracts were mock depleted (lanes 1–4), FANCI depleted (lanes 5–8) or FANCI depleted and treated with MG132 (lanes 9–12). Chromatin was replicated in the extracts, and chromatin-containing extract aliquots were taken at indicated time points and analyzed for FANCD2, FANCI and BLMcx members.
	Figure 5. FANCD2 regulates DNA DSB-triggered hyperphosphorylation of BLM and RPA2 independently of FANCI. S-phase egg extracts were mock depleted (lanes 1–3), FANCD2 depleted (lanes 4–6) or FANCI depleted (lanes 7–9), and supplemented with 50 ng/μl dsDNA fragments. Extract aliquots were taken at the indicated time points and analyzed for FANCD2, FANCI, BLM and RPA2.
	Figure 6. FANCD2-dependent BLM regulation is conserved in human cells. (A) Human BLM forms a constitutive complex with non-ubiquitinated FANCD2. Left panel: WCE were prepared from PD20 + D2 cells (lanes 1 and 2) and subjected to IP with rabbit IgG (lane 3), FANCD2 antibody (lanes 4 and 5) or BLM antibody (lanes 6 and 7). Input and equal volumes of IP samples were analyzed for presence of FANCD2 and BLM. Right panel: The same samples shown in the left panel were reanalyzed by extended gel electrophoresis. Sample volumes were adjusted to contain equal amounts of FANCD2 to better discern between non-ubiquitinated and monoubiquitinated FANCD2 isoforms. N.B.: to achieve equal FANCD2 protein concentrations in WCE and IP lanes, 1/30 of the original sample volumes were loaded in lanes 1, 2, 4 and 5. (B) Left panel: Human FANCD2 supports BLM protein stability. WCE were prepared from human PD20 + D2 cells (lanes 1 and 2) and PD20 cells (lanes 3 and 4) that had been untreated (lanes 1 and 3) or treated with 30 µM APH (lanes 2 and 4) and analyzed for FANCD2 and BLMcx members. Middle panel: Human FANCD2 mediates BLMcx chromatin recruitment. PD20 + D2 cells (lanes 1 and 3) and PD20 cells (lanes 2 and 4) were untreated (lanes 1 and 2) or treated with 30 µM APH for 3 h (lanes 3 and 4). Chromatin fractions were isolated from the cells and analyzed for presence of FANCD2, BLM and TOP3a. Histone H3: loading control. Right panel: Human FANCD2 is crucial for BLMcx assembly. WCE from untreated or APH-treated PD20 + D2 and PD20 cells were subjected to IP with rabbit IgG (lanes 1 and 4) or BLM antibody (lanes 2, 3, 5 and 6), and IP samples were analyzed for the presence of FANCD2 and BLMcx members.
	Figure 7. Human FANCD2 and BLM act in one pathway to mediate replication fork restart and suppression of new origin firing. (A) Human cell types used for DNA fiber analysis: wild type (PD20 + D2, siControl), FANCD2 deficient (PD20, siControl), BLM deficient (PD20 + D2, siBLM) and FANCD2/BLM double deficient (PD20, siBLM). (B) Images of DNA fibers with a schematic of defining sites of replication. Red tracts: DigU; green tracts: BioU. (C) FANCD2 and BLM act in a common pathway to mediate replication fork restart after replication blockade. The efficiency of replication restart in wild-type, FANCD2-deficient, BLM-deficient and FANCD2/BLM double-deficient cells was measured as the number of restarted replication forks after APH-mediated fork stalling (DigU→BioU tracts), compared with the total number of DigU-labeled tracts (DigU plus DigU→BioU). (D) FANCD2 and BLM act in concert to suppress new origin firing during replication blockade. The number of new sites of replication originating during the 40 min recovery period after APH treatment was compared between wild-type, FANCD2-deficient, BLM-deficient and FANCD2/BLM double-deficient cells. New origins of replication were measured as the number of green-only (BioU) tracts per unit length. ***P < 0.0001.
	Figure 8. Human BLM acts independently of FANCD2 to maintain velocity of restarted replication forks after APH treatment. (A) BLM maintains replication fork velocity in unperturbed conditions independently of FANCD2. BioU tract length distributions were determined on DigU→BioU double-labeled DNA fibers isolated from untreated (NT) wild-type, FANCD2-deficient, BLM-deficient or FANCD2/BLM double-deficient cells. (B–D) BLM maintains replication fork velocity of restarted forks independently of FANCD2. BioU tract length distributions were determined on double-labeled DNA fibers before (NT) and after APH treatment and compared between wild-type and (B) FANCD2-deficient cells, (C) BLM-deficient cells and (D) FANCD2/BLM double-deficient cells. For A–D, median tract lengths are indicated below each panel. Insets: Cumulative distributions (top) and plotted median tract lengths (bottom).
	Figure 9. Human FANCD2 acts independently of BLM to protect replication forks from degradation. Lengths of nascent replication fork tracts indicating fork stability (labeled with DigU only) were measured before (NT) and after 6 h of APH treatment. Preformed DigU tract lengths shorten during APH-treatment in (A) FANCD2-deficient (PD20) cells compared with wild-type (PD20 + D2) cells and in (B) FANCD2/BLM double-deficient (PD20, siBLM) cells compared with wild-type (PD20 + D2) cells. (C) Preformed DigU tract lengths do not shorten during APH-treatment in BLM-deficient (PD20 + D2, siBLM). Median tract lengths are indicated below each panel. Insets: Cumulative distributions (top) and plotted median tract lengths (bottom).

Ben-Yehoyada, Checkpoint signaling from a single DNA interstrand crosslink. 2009, Pubmed, Xenbase

Ben-Yehoyada, Checkpoint signaling from a single DNA interstrand crosslink. 2009, Pubmed , Xenbase
Chabosseau, Pyrimidine pool imbalance induced by BLM helicase deficiency contributes to genetic instability in Bloom syndrome. 2011, Pubmed
Chen, Binding and activation of DNA topoisomerase III by the Rmi1 subunit. 2007, Pubmed
Crossan, Disruption of mouse Slx4, a regulator of structure-specific nucleases, phenocopies Fanconi anemia. 2011, Pubmed
D'Andrea, Susceptibility pathways in Fanconi's anemia and breast cancer. 2010, Pubmed
Davies, Role for BLM in replication-fork restart and suppression of origin firing after replicative stress. 2007, Pubmed
Davies, Phosphorylation of the Bloom's syndrome helicase and its role in recovery from S-phase arrest. 2004, Pubmed
Deans, FANCM connects the genome instability disorders Bloom's Syndrome and Fanconi Anemia. 2009, Pubmed
Enomoto, [Function of RecQ family helicases and Bloom's syndrome]. 2001, Pubmed
Garcia-Higuera, Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. 2001, Pubmed
Hemphill, Topo IIIalpha and BLM act within the Fanconi anemia pathway in response to DNA-crosslinking agents. 2009, Pubmed
Hirano, Functional relationships of FANCC to homologous recombination, translesion synthesis, and BLM. 2005, Pubmed
Kee, Expanded roles of the Fanconi anemia pathway in preserving genomic stability. 2010, Pubmed
Kim, Mutations of the SLX4 gene in Fanconi anemia. 2011, Pubmed
Knipscheer, The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. 2009, Pubmed , Xenbase
Kratz, Deficiency of FANCD2-associated nuclease KIAA1018/FAN1 sensitizes cells to interstrand crosslinking agents. 2010, Pubmed
Li, Absence of BLM leads to accumulation of chromosomal DNA breaks during both unperturbed and disrupted S phases. 2004, Pubmed , Xenbase
Liu, FAN1 acts with FANCI-FANCD2 to promote DNA interstrand cross-link repair. 2010, Pubmed
Liu, More complexity to the Bloom's syndrome complex. 2008, Pubmed
MacKay, Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA damage by monoubiquitinated FANCD2. 2010, Pubmed
Maresca, Methods for studying spindle assembly and chromosome condensation in Xenopus egg extracts. 2006, Pubmed , Xenbase
Meetei, A multiprotein nuclear complex connects Fanconi anemia and Bloom syndrome. 2003, Pubmed
Meetei, A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M. 2005, Pubmed
Mosedale, The vertebrate Hef ortholog is a component of the Fanconi anemia tumor-suppressor pathway. 2005, Pubmed
Murray, Cell cycle extracts. 1991, Pubmed
Olson, RPA2 is a direct downstream target for ATR to regulate the S-phase checkpoint. 2006, Pubmed
Petermann, Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair. 2010, Pubmed
Petermann, Pathways of mammalian replication fork restart. 2010, Pubmed
Pichierri, BLM and the FANC proteins collaborate in a common pathway in response to stalled replication forks. 2004, Pubmed
Rao, Endogenous gamma-H2AX-ATM-Chk2 checkpoint activation in Bloom's syndrome helicase deficient cells is related to DNA replication arrested forks. 2007, Pubmed
Raynard, A double Holliday junction dissolvasome comprising BLM, topoisomerase IIIalpha, and BLAP75. 2006, Pubmed
Sareen, Fanconi anemia proteins FANCD2 and FANCI exhibit different DNA damage responses during S-phase. 2012, Pubmed , Xenbase
Schlacher, Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. 2011, Pubmed
Schlacher, A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. 2012, Pubmed
Singh, Roles of RECQ helicases in recombination based DNA repair, genomic stability and aging. 2009, Pubmed
Singh, BLAP18/RMI2, a novel OB-fold-containing protein, is an essential component of the Bloom helicase-double Holliday junction dissolvasome. 2008, Pubmed
Smogorzewska, Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. 2007, Pubmed
Smogorzewska, A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair. 2010, Pubmed
Sobeck, Fanconi anemia proteins are required to prevent accumulation of replication-associated DNA double-strand breaks. 2006, Pubmed , Xenbase
Sobeck, DNA structure-induced recruitment and activation of the Fanconi anemia pathway protein FANCD2. 2007, Pubmed , Xenbase
Song, A novel role for Fanconi anemia (FA) pathway effector protein FANCD2 in cell cycle progression of untransformed primary human cells. 2010, Pubmed , Xenbase
Stoepker, SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. 2011, Pubmed
Sugimura, Non-denaturing fluorescence in situ hybridization to find replication origins in a specific genome region on the DNA fiber. 2007, Pubmed
Suhasini, Interaction between the helicases genetically linked to Fanconi anemia group J and Bloom's syndrome. 2011, Pubmed
Summers, Phosphorylation: the molecular switch of double-strand break repair. 2011, Pubmed
Taniguchi, S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. 2002, Pubmed
Vassin, Human RPA phosphorylation by ATR stimulates DNA synthesis and prevents ssDNA accumulation during DNA-replication stress. 2009, Pubmed
Wang, Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. 2007, Pubmed
Wold, Replication protein A: a heterotrimeric, single-stranded DNA-binding protein required for eukaryotic DNA metabolism. 1997, Pubmed
Wu, BLAP75/RMI1 promotes the BLM-dependent dissolution of homologous recombination intermediates. 2006, Pubmed
Wu, The Bloom's syndrome helicase suppresses crossing over during homologous recombination. 2003, Pubmed
Xu, RMI, a new OB-fold complex essential for Bloom syndrome protein to maintain genome stability. 2008, Pubmed
Yamamoto, Involvement of SLX4 in interstrand cross-link repair is regulated by the Fanconi anemia pathway. 2011, Pubmed
Yang, RMI1 promotes DNA replication fork progression and recovery from replication fork stress. 2012, Pubmed
Yin, BLAP75, an essential component of Bloom's syndrome protein complexes that maintain genome integrity. 2005, Pubmed
Zou, Functions of human replication protein A (RPA): from DNA replication to DNA damage and stress responses. 2006, Pubmed